Correction to: A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY tract cancers (BTC) at high risk for recurrence: PURITY study

Monica Niger,Federico Nichetti,Lorenzo Fornaro,Chiara Pircher,Federica Morano,Federica Palermo,Lorenza Rimassa,Tiziana Pressiani,Rossana Berardi,Andrea Casadei Gardini,Elisa Sperti,Lisa Salvatore,Davide Melisi,Francesca Bergamo,Salvatore Siena,Stefania Mosconi,Rafaella Longarini,Giuseppina Arcangeli,Salvatore Corallo,Laura Delliponti,Stefano Tamberi,Elena Fea,Giovanni Brandi,Ilario Giovanni Rapposelli,Massimiliano Salati,Paolo Baili,Rosalba Miceli,Silva Ljevar,Ilaria Cavallo,Elisa Sottotetti,Antonia Martinetti,Michele Droz Dit Busset,Carlo Sposito,Maria Di Bartolomeo,Filippo Pietrantonio,Filippo De Braud,Vincenzo Mazzaferro

doi:10.1186/s12885-024-12328-0

Correction to: A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY tract cancers (BTC) at high risk for recurrence: PURITY study

Monica Niger, Federico Nichetti + Show 35 more

Open Access

https://doi.org/10.1186/s12885-024-12328-0

Copy DOI

Journal: BMC Cancer	Publication Date: May 6, 2024
License type: cc-by

#Gemcitabine And Nabpaclitaxel #Cisplatin Plus + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Correction to: A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY tract cancers (BTC) at high risk for recurrence: PURITY study

Full Text